SCHEMBL30294466

SCHEMBL30294466

Cc1cc(F)ccc1Nc1nc(C#N)c(Cl)cc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLCN2 P51788 1/20 0.43
▸ MKNK2 Q9HBH9 1/20 0.43
▸ MAPK3 P27361 1/20 0.43
▸ MAPK13 O15264 1/20 0.43
▸ MAPK12 P53778 1/20 0.43
▸ MAPK11 Q15759 1/20 0.43
▸ MAPK14 Q16539 1/20 0.43
▸ FTO Q9C0B1 1/20 0.41
▸ FABP3 P05413 1/20 0.38
▸ FABP4 P15090 1/20 0.38
▸ DHODH Q02127 1/20 0.36
▸ PIK3CA P42336 3/20 0.36
▸ AVPR2 P30518 1/20 0.36
▸ OXTR P30559 1/20 0.36
▸ AVPR1A P37288 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ LYN P07948 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22853078 1.00 CLCN2 (0.43) CLCN2MKNK2MAPK3MAPK13MAPK12
SCHEMBL30294640 0.89 MAPK3 (0.41) MKNK2MAPK3MAPK13MAPK12MAPK11
SCHEMBL22853043 0.89 MAPK3 (0.41) MKNK2MAPK3MAPK13MAPK12MAPK11
SCHEMBL30294810 0.87 P2RX7 (0.37) CLCN2MAPK3FTOFABP3FABP4
SCHEMBL22853008 0.85 CLCN2 (0.47) CLCN2MKNK2MAPK3MAPK13MAPK12
SCHEMBL22853004 0.85 FTO (0.47) CLCN2MKNK2MAPK3MAPK13MAPK12
SCHEMBL30294418 0.85 FTO (0.47) CLCN2MKNK2MAPK3MAPK13MAPK12
SCHEMBL30294338 0.85 CLCN2 (0.47) CLCN2MKNK2MAPK3MAPK13MAPK12
SCHEMBL22853352 0.83 DHODH (0.43) DHODH
SCHEMBL30294359 0.83 DHODH (0.43) DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B CLCN2 192/4885MKNK2 1822/4885MAPK3 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback